Abstract Types

Clinical Review Abstract

Late-Breaking Abstract

Trials in Progress Abstract

Abstracts selected for publication but not presentation at the Annual Meeting

Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy

Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

Pancreatic Cancer

Gastrointestinal (Noncolorectal) Cancer

2013 ASCO Annual Meeting

Abstract No:

J Clin Oncol 31, 2013 (suppl; abstr 4012)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Daniel Virgil Thomas Catenacci, Nathan Bahary, Sreenivasa R. Nattam, Robert de Wilton Marsh, James Alfred Wallace, Lakshmi Rajdev, Deirdre Jill Cohen, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. Stiff, Sachdev P. Thomas, Peng Xu, Les Henderson, Margit Naomi Horiba, Michael Vannier, Theodore Karrison, Walter Michael Stadler, Hedy Lee Kindler; University of Chicago, Chicago, IL; University of Pittsburgh Medical Center, Pittsburgh, PA; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Kellogg Cancer Center NorthShore University Health System, Evanston, IL; Ingalls Memorial Hospital/Cancer Research Center, Harvey, IL; Montefiore Medical Center, Bronx, NY; New York University Cancer Institute, New York, NY; St. John's Mercy Medical Center, St. Louis, MO; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Loyola University Medical Center, Maywood, IL; Illinois Cancer Care, Peoria, IL; University of Maryland, Baltimore, MD; The University of Chicago Medical Center, Chicago, IL; The University of Chicago, Chicago, IL

Abstract Disclosures


Background: Sonic Hh (SHh), the ligand for the Hh pathway, is over-expressed in >80% of PC. V had activity in preclinical murine PC models leading to increased tumor perfusion, enhanced tumor delivery of G, and an improvement in survival. Methods: We conducted a placebo-controlled, phase IB/randomized phase II trial of GV or GP. Eligible pts, KPS 80-100, had untreated metastatic PC, or had completed adjuvant therapy > 6 months (mo) prior. Primary endpoint: progression-free survival (PFS). Correlatives: serial SHh serum levels; serial perfusion CT imaging. All pts received G 1000mg/m2over 30 minutes, days (D) 1, 8, 15, Q28D. A lead-in phase IB was performed. Pts, stratified by KPS (80 v 90/100), and disease status (newly diagnosed/recurrent), were randomized to V (150 mg PO daily) or P. For pts on P, cross-over was allowed at progression. Assuming a mPFS of 3.5 months for GP and 5.7 months for GV (HR=0.61), a sample size of 106 subjects (53 per group) provided 85% power to detect this difference, using a one-sided test at the 0.10 significance level. Results: No safety issues were identified in 7 pts enrolled in the phase IB study. The phase II study enrolled 106 evaluable pts (V/P 53/53) at 13 sites 2/10-6/12. Pt characteristics: median age 65/64 (range 52-82/39-83); KPS (% pts) 80: 38/30; 90: 26/38; 100: 36/32; newly diagnosed 91%/91%; recurrent: 9%/9%. Grade 3/4 toxicity (V/P, % pts, >5% in either arm): neutropenia 32/28; lymphopenia 4/15; thrombocytopenia 9/11; anemia 9/23; hyponatremia 4/15; fatigue 13/8; hyperglycemia 23/19; elevated ALT 13/9; hyperbilirubinemia 11/6; nausea 11/11. Response (%): CR 0/2, PR 8/11, SD 51/38. mPFS: 4.0/2.5 mo (95% CI: 2.5-5.3/1.9-3.8; HR 0.81 [0.54-1.21], p=0.30). 22 pts (42%) on GP crossed over to GV at progression. mOS: 6.9/6.1 mo (95% CI:5.8-8.0/5.0-8.0, HR 1.04, [0.69-1.58], p=0.84). Updated laboratory/radiological correlatives will be presented. Conclusions: Toxicity between the groups was similar. The addition of V to G in an unselected cohort does not improve response, PFS, or OS in pts with metastatic PC. Funding NCI N01-CM-62201. Clinical trial information: NCT01064622.


  Other Abstracts in this Sub-Category:


1. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA4003 First Author: P. Hammel
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer


2. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA4004 First Author: G. W. Middleton
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer


3. Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

Meeting: 2013 ASCO Annual Meeting Abstract No: 4005^ First Author: D. D. Von Hoff
Category: Gastrointestinal (Noncolorectal) Cancer - Pancreatic Cancer